Target Corporation — Form 10-K Summary
Period clarification: The request metadata says “2015 Q4,” but this filing reports fiscal 2016, the 52 weeks ended January 28, 2017, with comparisons to fiscal 2015 and 2014. Target is a U.S. general-merchandise retailer operating stores and digital channels as one segment. The company had 1,802 U.S. stores at year-end. Its Canadian retail operations are discontinued; CVS acquired its pharmacy and clinic businesses in December 2015.
Financial performance
| Metric | Fiscal 2016 | Fiscal 2015 | Change or context |
|---|---|---|---|
| Sales | $69.495 billion | $73.785 billion | Down 5.8%; chiefly reflects the $3.815 billion reduction associated with the pharmacy sale and comparable sales decline. |
| Comparable sales | Down 0.5% | Up 2.1% | Store comps fell 1.5%; digital sales growth of 27% contributed 1.0 percentage point. Traffic declined 0.8%. |
| Gross margin | $20.623 billion; 29.7% | $21.788 billion; 29.5% | Margin rate improved 0.2 percentage point. |
| SG&A expense rate | 19.2% | 19.6% | Lower rate reflected the pharmacy transaction and technology savings, partly offset by higher store hourly payroll. |
| Operating earnings before interest and taxes | $4.969 billion | $5.530 billion | Down 10.1%; prior-year results included the $620 million pharmacy-sale gain. |
| Net interest expense | $1.004 billion | $607 million | 2016 included a $422 million loss on early debt retirement. |
| Continuing-operations net earnings | $2.669 billion | $3.321 billion | Diluted EPS was $4.58 versus $5.25. |
| Adjusted diluted EPS | $5.01 | $4.69 | Non-GAAP measure excluding specified unusual items; up 6.7%. |
| Net earnings, including discontinued operations | $2.737 billion | $3.363 billion | Fiscal 2016 included $68 million of income from discontinued operations. |
| Operating cash flow from continuing operations | $5.329 billion | $5.254 billion | Up from the prior year. |
| Capital expenditures | $1.547 billion | $1.438 billion | Higher investment in stores and guest experience. |
| Cash and cash equivalents | $2.512 billion | $4.046 billion | Decrease reflected deployment of pharmacy-sale proceeds and related taxes. |
| Total assets | $37.431 billion | $40.262 billion | Year-end balance-sheet measure. |
| Long-term debt, including current portion | $12.749 billion | $12.760 billion | Near unchanged; includes current debt and other borrowings. |
Material changes and unusual items
- CVS purchased Target’s pharmacy and clinic businesses for approximately $1.9 billion in December 2015. Target recognized a $620 million gain in fiscal 2015 and continues to receive occupancy-related income under its agreement with CVS.
- Fiscal 2016 sales fell partly because pharmacy and clinic sales were no longer consolidated. The comparable-sales measure excludes those businesses from the prior-year comparison.
- Target recorded a $422 million loss on early debt retirement in fiscal 2016, compared with $285 million in fiscal 2014.
- The company’s Canada exit remains in discontinued operations. Fiscal 2014 included $5.1 billion of pretax exit charges; fiscal 2016 included $13 million of pretax exit costs and $68 million of after-tax discontinued-operations income.
- Target repurchased 50.9 million shares for $3.686 billion in fiscal 2016 and paid $1.348 billion in dividends. Management reported $5.0 billion returned to shareholders through dividends and repurchases.
Liquidity, debt, outlook and risks
- Target reported a $2.5 billion committed revolving credit facility expiring in October 2021, with no amount outstanding at year-end. It also reported access to commercial paper and stated that available liquidity should support operations, investment, debt maturities, dividends and repurchases for the foreseeable future. The company reported compliance with debt covenants.
- Contractual obligations totaled $26.506 billion, including $11.814 billion of long-term debt principal, $6.308 billion of future debt interest, and $3.876 billion of operating lease payments. These are scheduled obligations, not all balance-sheet debt.
- Management expected fiscal 2017 capital expenditures of approximately $2.0 billion to $2.5 billion, emphasizing store remodels, flexible-format stores and supply-chain investment. The filing provides no specific fiscal 2017 earnings or comparable-sales guidance.
- Management attributed gross-margin-rate improvement to the pharmacy transaction and favorable sales mix, partly offset by higher shipping and digital fulfillment costs. Digital comparable sales grew 27%, while store traffic and overall comparable sales declined.
- Key disclosed risks include intense retail competition and changing consumer preferences; execution and returns on digital, technology and store investments; cybersecurity and guest-data privacy; supply-chain disruption, import costs and trade-policy changes; dependence on U.S. consumer conditions; labor costs; and reliance on third parties, particularly CVS.
- Target disclosed securities and ERISA class actions concerning prior Canada disclosures; motions to dismiss were pending. The filing also describes California environmental-law allegations for which no formal action or specific relief had been sought as of the filing. Management stated that it did not believe identified claims would be material, while acknowledging litigation uncertainty.
- Target said the significant 2013 data-breach claims had largely been resolved; remaining accruals were immaterial at year-end. Cumulative net breach-related expenses were $202 million after insurance recoveries.
- The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting.
Most important facts for investors to verify
- Separate the underlying sales trend from the pharmacy-sale effect: confirm comparable-sales definitions and the trajectory of store traffic versus digital growth.
- Assess continuing-operations earnings against reported and adjusted EPS, including the $422 million debt-retirement loss and the prior-year pharmacy-sale gain.
- Review cash conversion, capital-spending plans, debt maturities, lease commitments and the effect of shareholder distributions on cash and equity.
- Monitor whether store remodels, flexible formats, digital fulfillment and supply-chain investments generate expected returns and improve sales and margins.
- Track CVS operating-agreement performance and the outcome of the Canada-related litigation and California environmental matter.